Emerging treatments for viral myocarditis

Author: Matsumori, Akira

Source: Future Cardiology, Volume 1, Number 5, September 2005 , pp. 683-692(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Although viral myocarditis has been mostly attributed to enterovirus and adenovirus infection, the importance of hepatitis C virus has recently been noted. Clinical trials of antiviral agents, such as interferons, are in progress, while new therapies such as viral vaccines, recombinant virus and virus receptors, are in preclinical development.Whereas immunosuppression with corticosteroids or cyclosporin is ineffective, immunosuppressors that do not promote viral replication, such as FTY720, and immunomodulation by interleukin-10, are promising new approaches. Inhibition of nuclear factor-κB, angiotensin II and endothelin effectively suppresses inflammation in experimental viral myocarditis. Embryonic stem cell therapy has been demonstrated to be beneficial; however, this requires further investigation.

Keywords: adenovirus; antiviral therapy; coxsackievirus; cytokine; hepatitis virus; immunomodulation; immunosuppression; myocarditis; nuclear factor-κB

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796678.1.5.683

Publication date: 2005-09-01

More about this publication?

Future Cardiology reflects the new era of cardiology and highlights new molecular approaches in advancing cardiovascular therapy. The journal publishes clinical research, commentary and therapeutic overviews highlighting optimal therapy and future options and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites